Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

Leukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, today announced that the U.S. Food and Drug Administration (FDA ...

Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...

If you watched "Chainsaw Man – The Movie: Reze Arc" and thought it looked different from TV anime's first season, you're dead ...

Missing Context in Single-Cell DataSingle-cell RNA sequencing has transformed biology by showing which genes are active in individual cells. However ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

HER2DX is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e.

BackgroundSepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It ...

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...